P- Reviewer: Chizzolini C, Martinez-Lostao L, Nas K, Rothschild BM, Song J S- Editor: Ji FF L- Editor: A E- Editor: Jiao XK
Published online Jul 12, 2015. doi: 10.5499/wjr.v5.i2.50
Peer-review started: January 24, 2015
First decision: February 7, 2015
Revised: April 29, 2015
Accepted: May 5, 2015
Article in press: May 6, 2015
Published online: July 12, 2015
Biologic agents have ushered a new era in the treatment of inflammatory rheumatic diseases. In recent years, several biologic agents have been approved by food and drug administration and have significantly improved outcomes for patients with immune mediated inflammatory disorders including rheumatic and inflammatory bowel diseases. The most common used biologic therapeutic agents are tumor necrosis factor inhibitors (etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab), an interleukin (IL)-6 inhibitor (tocilizumab), an IL-1 receptor antagonist (anakinra), an anti-CD-20 antibody (rituximab), and a T cell co-stimulation modulator (abatacept). Their use during pregnancy has been controversial because of absence of controlled studies which have enrolled pregnant women. This brief overview provides published data on use of biologic agents for the treatment of rheumatic diseases in pregnancy.
Core tip: Biologic agents are increasingly being used in the treatment of rheumatic diseases. This article presents published data on use of biologic agents in pregnant women with rheumatic diseases.
- Citation: Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. World J Rheumatol 2015; 5(2): 50-58
- URL: https://www.wjgnet.com/2220-3214/full/v5/i2/50.htm
- DOI: https://dx.doi.org/10.5499/wjr.v5.i2.50
Most of the women with rheumatic diseases experience clinical remission during pregnancy, however in some cases, it is needed to continue the treatment throughout pregnancy[1,2]. Few studies have suggested that high disease activity in rheumatic diseases throughout pregnancy may lead to increased risks for preeclampsia, cesarean delivery, prematurity, low birth weight[6,7], and intrauterine growth restriction. Owing to the fact that important antirheumatic agents such as methotrexate and leflunomide have teratogenic effects, the treatment options are limited, and biological agents may be therapeutic alternative in pregnant women with high disease activity.
Since cytokines play a crucial role in host defense against infections, cytokine blockade is associated with increased risk of opportunistic infections. Previous studies have suggested an increased risk of bacterial, viral and fungal infections due to mycobacterium, salmonella, listeria, hepatitis B and C, herpes, histoplasma, cryptococcus, coccidioides, candida, aspergillus and pneumocystis. Pregnancy is a period of relative immunosuppression, thus use of biologic agents during pregnancy may further increase the risk of infections.
Since no drug trials have been performed in pregnant women to assess the risk of administration of biologic agents, safety of these agents during pregnancy is still a matter of debate. However, cumulative data suggest that frequency of birth defects after prenatal exposure to biologic agents does not seem to be higher than that occurs in the general population.
A PubMed literature search (2000-2015) was performed to identify studies with human data on pregnancy outcomes after exposure to biologic agents during pregnancy. Search strategy was restricted to the articles published in English and Turkish and included the following search terms “tumor necrosis factor (TNF) inhibitors”, “etanercept”, “infliximab”, “adalimumab”, “certolizumab”, “golimumab”, “tocilizumab”, “anakinra”, “rituximab”, “abatacept”, and “pregnancy”. First, titles and abstracts of all 931 references were screened; articles which have insufficient data or do not address the topic of the interest were excluded. Inclusion criteria were data on pregnancy outcomes in patients who were exposed to biologic agents before conception and throughout pregnancy. Additionally a hand-search was made looking for the reference lists of the applicable publications. Adequate documentation was found in 10 reviews, 10 registries, 17 case series and 18 case reports. Published data on reports of biologic therapies are summarized in Table 1.
|Ref.||Study design||No. of pregnancies||Diagnosis||Biologic agent||Time of exposure||Reported outcomes|
|Bortlik et al||Case series||41||27 CD 14 UK||INF ETA||NR||5 spontaneous abortion 2 elective termination 1 congenital malformation (mild hip dysplasia)|
|Burt et al||Case report||1||CD||INF||T1||Healthy infant at 36 wk of gestation|
|Sinha and Patient||Case report||1||RA||ETA||C + T1 + T2 + T3||Healthy term delivery|
|Takayama et al||Case report||1||BD||INF||T2 + T3 (discontinued at 32 wk of gestation)||Healthy term delivery|
|Coburn et al||Case report||1||CD||ADA||T2 + T3||Healthy term delivery|
|Akinci et al||Case report||1||AS||INF||T2 + T3||Healthy term delivery|
|Kraemer et al||Case report||1||Takayasu arteritis||ADA||C + T1 + T2 + T3||Healthy term delivery|
|Hou et al||Case report||1||CD||INF||T1 + T2 + T3 (discontinued at 33 wk of gestation)||Healthy term delivery|
|Umeda et al||Case report||1||RA||ETA||T2 + T3||Healthy term delivery|
|Puig et al||Case report||1||Psoriasis||INF||T1 + T2 + T3 (last infusion at 29 wk of gestation)||Healthy term delivery|
|Jang et al||Case report||1||CD||INF||C + T1||Healthy term delivery|
|Vesga et al||Case report||1||CD||ADA||C + T1 + T2 + T3||Healthy term delivery|
|Mahadevan et al||Case series||10||CD||INF||NR||10 live birth 3 premature delivery 0 spontaneous abortion 0 elective termination 0 congenital malformation|
|Berthelot et al||Case series||15||SpA, RA, JIA, PsA||3 INF 2 ADA 10 ETA||NR||2 spontaneous abortion (ETA) 1 elective termination (ETA)|
|Rump et al||Case series||8 pregnancies in 5 women||4 RA 1 AS||ETA||NR||1 spontaneous abortion 1 megacolon congenitum|
|Arguelles-Arias et al||Case series||12||8 CD 4 UK||INF||1 C 2 T1 3 T1 + T2 6 T1 + T2 + T3||1 premature delivery No congenital malformation, IUGR, SGA|
|Diav-Citrin et al||Registry||83||CD, RA, UK, UndA, PsA, AS, BD||35 INF 25 ETA 23 ADA||81 T1 2 T2 or T3||67 live birth 9 spontaneous abortion 5 elective termination 0 congenital malformation|
|Chakravarty et al||Registry||17||RA||15 ETA 2 INF||NR||1 spontaneous abortion (ETA) 1 elective termination (ETA) No congenital malformation, IUGR, SGA|
|Hyrich et al||Registry||23||RA||17 ETA 3 INF 3 ADA||NR||14 live births 6 spontaneous abortion (4 ETA, 1 INF, 1 ADA) 3 elective termination (all in patients receiving ETA, 2 also receiving MTX)|
|Carter et al||Registry||41||Autoimmune diseases||22 ETA 19 INF||NR||24 (59%) children had one or more congenital deformities such as vertebral deformities, anal atresia, cardiac anomalies, tracheoesophageal fistula, renal anomalies and limb defects, which were the features of VACTERL|
|Offiah et al||Case report||1||PsA||INF||C + T1 + T2 + T3||Transient collodion membrane|
|Guiddir et al||Case series||4||UK||INF||T1 + T2 + T3||4 neonatal neutropenia|
|Grosen et al||Case report||1||UK||INF||T3||Ten days after INF infusion serum sickness-like reaction in the mother (at 35 wk of gestation) Preterm infant without any congenital anomaly|
|Ergaz et al||Case report||1||RA||ETA (also receiving prednisone and hydroxychloroquine||C + T1 + T2 + T3||Congenital fulminant kaposiform hemangioendothelioma|
|Hultzsch et al||Case series||26||19 RA 6 AS 1 PsA||ETA||T1||19 live birth 5 premature delivery 5 spontaneous abortion 2 elective termination 1 congenital renal agenesis 1 hypoplastic left heart syndrome + hypospadias 1 Wolff Parkinson White syndrome|
|Weber-Schoendorfer et al||Case series||53||Autoimmune diseases||28 ADA 25 INF||T1||46 live birth (24 ADA, 22 INF) 8 premature delivery (4 ADA, 4 INF) 4 spontaneous abortion (2 ADA, 2 INF) 3 elective termination (2 ADA, 1 INF) 1 autosomal disease inherited from his father (ADA) 1 ventricular septal defect (INF)|
|Johnson et al||Case series||34||RA||ADA||T1||29 live birth 5 spontaneous abortion 1 undescended testicle 1 microcephaly|
|Katz et al||Registry||64||82 CD 8 RA 2 JRA 1 UK||INF||53 within 3 mo of C 25 within 3 mo prior to C 28 within 3 mo prior to C + T1 30 T1 7 > 3 mo prior to C 6 unknown||64 live birth 14 spontaneous abortion 18 therapeutic termination 0 congenital malformation|
|Cheent et al||Case report||1||CD||INF||C + T1 + T2 + T3||No congenital malformation, IUGR BCG vaccination at age of 3 mo Died from disseminated BCG disease at age of 4.5 mo|
|Mahadevan et al||Registry||190||124 CD 56 other diseases||CZP||NR||132 live birth 36 spontaneous abortion 22 elective termination vesicoureteral reflux, congenital morbus, congenital megacolon, congenital talipes equinovarus, aortic arch anomaly, and unilateral hydronephrosis in four infants|
|Lau et al||Case series||40||24 RA 1 PsA 5 AS 10 UK||GLM||NR||19 live birth 13 spontaneous abortion 7 induced abortion 1 ectopic pregnancy 1 unspecific congenital malformation leading to intrauterine death and induced abortion|
|Berger et al||Case report||1||AOSD||Anakinra||C + T1 + T2 + T3||Term delivery complicated with placental retention|
|Chang et al||Case series||9||CAPS||Anakinra||C + T1 + T2 + T3||No preterm birth or serious complication Fetal loss of a twin due to renal agenesis. DNA testing revealed the same NLRP3 c.785T > C, p.V262A mutation as the mother|
|Rubbert-Roth et al||Registry||33||RA||TCZ||NR||7 spontaneous abortion 13 elective termination 11 term delivery (1 infant died from ARDS 3 d after emergency cesarean section for intrapartum fetomaternal hemorrhage due to placenta previa)|
|Ojeda-Uribe et al||Case series||3||Autoimmune diseases||2 RTX 1 abatacept||T1||3 healthy term delivery|
|Chakravarty et al||Registry||153||Autoimmune diseases||RTX||NR||90 live birth 33 spontaneous abortion 28 elective termination 22 premature delivery 1 maternal death from autoimmune thrombocytopenia 1 perinatal death 11 perinatal hematologic anomalies 4 perinatal infections 1 congenital talipes equinovarus 1 cardiac malformation|
|Sangle et al||Case series||6||5 SLE 1 WG||RTX||8-22 mo prior to C||4 healthy term delivery (3 SLE, 1 WG) 1 preterm low birth weight (SLE) 1 esophageal atresia (SLE)|
|Pendergraft et al||Case report||1||Autoimmune vasculitis||RTX||7.5 mo prior to C||Spontaneous abortion (Beckwith-Wiedemann Syndrome)|
Efficacy of TNF inhibitors has been demonstrated in reducing disease activity and joint damage and improving health-related quality of life in the patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), and ankylosing spondylitis. Most frequently used TNF inhibitors include etanercept, a soluble p75 TNF-receptor and IgG1 Fc fusion protein; infliximab, a human-murine IgG1 anti-TNF monoclonal antibody; adalimumab, a human IgG1 anti-TNF monoclonal antibody; certolizumab pegol, a pegylated Fab fragment of humanized anti-TNF monoclonal antibody; and golimumab, fully humanized TNF-alpha monoclonal antibody.
TNF inhibitors have been rated as Food and Drug Administration (FDA) category B (No evidence of a risk to the fetus was found in animal toxicity studies; however there are no controlled studies which have enrolled pregnant women). TNF inhibitors do not actively cross the placenta during the first trimester and organogenesis, but they are transferred across the placenta during the late second and third trimester. These can be found in newborn’s cord blood in levels that exceed those of the corresponding maternal serum[16,17]. Additionally, they are detectable in blood of the infant for more than six months after the birth, reducing the safety of vaccination. Certolizumab does not contain Fc region, thus it does not actively cross the placenta.
Use of TNF inhibitors has been reported in almost 2000 pregnancies of the patients with rheumatic diseases, inflammatory bowel diseases and psoriasis. Based on the published data from case reports[19-29], case series[30-34] and registries on etanercept, infliximab, adalimumab, golimumab and certolizumab[35-37], it has been found that preconception exposure to biologic agents or use of them during pregnancy including first, second and third trimesters is not associated with increased risk of adverse pregnancy outcomes, malformations or birth defects compared with general population.
An FDA database review revealed 61 birth defects in 41 children born to mothers receiving TNF inhibitors. Of these mothers, 22 received etanercept and 19 received infliximab. The most common congenital anomalies were heart defects, spinal deformities, imperforate anus, tracheoesophageal fistula, renal anomalies and limb defects, which were the features of vertebral defects, anal atresia, cardiac defects, tracheo-esophageal fistula, renal anomalies, and limb abnormalities association. These anomalies were found to be linked with use of TNF antagonists and it was suggested that these agents should not be administered during pregnancy.
British society for rheumatology biologics register (BSRBR) is a database which keeps information about RA patients taking TNF antagonists. Between 2005 and 2006, 11473 patients were registered with the BSRBR. Of these patients, 17 received etanercept, 3 received infliximab and 3 received adalimumab. No congenital malformation was observed. After this report, another BSRBR report which assesses the outcomes of 118 pregnancies in patients who were exposed to TNF antagonists was published in 2008. The rate of miscarriage was 27% in the patients who received anti-TNF at the time of conception (group 1), 17% in those with prior exposure to anti-TNF (group 2) and 10% in those who were never exposed to anti-TNF (group 3). The rate of premature delivery was 26% in group 1, 17% in group 2, and 20% in group 3. A perinatal death causing from hypoxia was reported in a patient who was exposed to etanercept at the time of conception. Additionally four cases of congenital anomalies were reported. In group 1, congenital hip dysplasia and pylorostenosis, and in group 2 Marcus Gunn syndrome and infantile hemangioma were observed. The authors suggested that treatment with TNF inhibitors might be linked with an increased risk of spontaneous abortion, however the effects of disease activity and other antirheumatic agents could not be eliminated.
Offiah et al reported a transient collodion membrane in a 2-d-old infant born to mother receiving infliximab for severe psoriasis and PsA throughout pregnancy in United States. The skin turned to normal at age 1 year with mineral oil treatment.
Guiddir et al reported four cases of severe neutropenia in newborn patients exposed to infliximab. High serum infliximab concentrations were detected several months after birth. It was suggested that the mononuclear phagocyte system of a newborn is inadequate to clear the antibody rapidly.
Tetralogy of Fallot, intestinal malrotation, hypothyroidism, intracranial and intrapulmonary hemorrhage, unilateral renal agenesis, serum sickness-like reaction (with infliximab)[35,42-44], infantile kaposiform hemangioendothelioma, Kasabach-Merritt syndrome, renal agenesis, urethral defects, cardiac conduction system abnormalities, pylorostenosis, congenital megacolon (with etanercept)[32,39,45,46], and ventricular septal defect, congenital hip dysplasia, spina bifida with hydrocephalus, aortic valve disease, corpus callosum agenesis, and congenital hypothyroidism (with adalimumab)[47,48] have been reported in the babies born to mothers directly exposed to TNF inhibitors during pregnancy. However rates of these anomalies have been found to be similar to those expected for the general population[35,46,49].
Cheent et al reported use of infliximab during pregnancy in a 28-year-old patient with Crohn’s disease. Newborn had no congenital malformation or intrauterine growth retardation. He was healthy until bacillus calmette-guerin (BCG) vaccine administered at the age of three months. One point five months later he died from disseminated BCG disease which was a rare life-threatening complication of BCG administration.
Certolizumab is different from other TNF inhibitors, it does not contain Fc region, thus it is not actively transported through the placenta. It has only minimal transplacental transmission to newborn via passive diffusion during first, second and third trimesters.
The Union Chimique Belge Pharma global safety database revealed 69.5% live birth rate in 190 pregnant women exposed to certolizumab. The rates of spontaneous abortions and elective terminations were 18.9% and 11.6%, respectively. Six birth defects were observed in four infants among all live births: vesicoureteral reflux, congenital morbus, congenital megacolon, congenital talipes equinovarus, aortic arch anomaly, and unilateral hydronephrosis. However these congenital anomalies were not thought to be associated with exposure to certolizumab. These pregnancy outcomes were comparable to those reported for united states general population (65% live births, 17% spontaneous abortions, and 18% elective abortions). In Pregnancy in Inflammatory Bowel Diseases and Neonatal Outcomes study where women with inflammatory bowel disease exposed to certolizumab in the third trimester of pregnancy were compared with unexposed group, it was suggested that use of certolizumab in the third trimester was not associated with increase in infant infection rates.
Golimumab is a newer TNF inhibitor and there is limited data on its use during pregnancy. In a study by Martin et al performed in cynomolgus monkeys received 25-50 mg/kg golimumab twice weekly during pregnancy, no effect was observed on pregnancy outcomes or fetal immune system. Experience with use of golimumab during pregnancy has been limited to conference abstracts. Lau et al reported pregnancy outcomes of 40 women exposed to golimumab at the American College of Rheumatology (ACR) Annual Meeting in 2013. Outcomes included one unspecific congenital anomaly, 19 live births, 13 spontaneous abortions and 7 induced abortions. Of 13 mothers with spontaneous abortion, 4 had concomitant methotrexate use.
Anakinra is a human IL-1 receptor antagonist certified by FDA for the therapy of RA patients with intermediate/high disease activity. It has been rated as FDA pregnancy category B. It has a half-life of 4-6 h. Because of its short half-life, discontinuance of anakinra before conception is not necessary. Experiences with use of anakinra during pregnancy are limited. Three pregnancies in patients received anakinra for the treatment of adult onset Still’s disease resulted in term live births[57,58]. Chang et al described outcomes of fifteen pregnancies in nine women receiving anakinra for the treatment of cryopyrin-associated periodic syndrome. Outcomes included 14 healthy term infants and one intrauterine fetal demise resulting from renal agenesis.
Tocilizumab is a humanized IL-6 receptor inhibitor used in the therapy of moderate to severe RA and polyarticular and systemic JIA. It is categorized as FDA pregnancy category C. Tocilizumab should be discontinued three months before conception. Experiences with use of tocilizumab during pregnancy were reported by Rubbert-Roth et al at the ACR Annual Meeting in 2010. Of 33 pregnancies, 13 resulted in induced abortion, 7 resulted in spontaneous abortion and 11 resulted in live births. Of 7 mothers with spontaneous abortion, 5 had concomitant methotrexate use.
Rituximab is a chimeric monoclonal antibody against the B cell surface antigen CD20. It is indicated for the treatment of severe refractory RA with inadequate response to TNF inhibitors, certain types of vasculitis, non-Hodgkin’s lymphoma and chronic lymphoid leukemia. It is classified as FDA category C, meaning “it has not been studied on pregnant women, however animal developmental toxicity studies have shown an adverse effects on the fetus”. It has no active transplacental passage during the first trimester and organogenesis, but actively crosses the placenta during the late second and third trimester, and may affect fetal and neonatal B cell development, causing increased risk for infections. Chakravarty et al reported pregnancy outcomes in 153 patients exposed to rituximab. Of these pregnancies, 90 resulted in live births, 22 resulted in prematurity and one resulted in perinatal death. 11 infants had hematologic abnormalities at birth (peripheral B-cell depletion, neutropenia, lymphopenia, thrombocytopenia and anemia) and four had perinatal infections. Two infants had congenital defects (congenital talipes equinovarus and cardiac malformation). Sangle et al reported pregnancy outcomes in 5 patients with systemic lupus erythematosus exposed to rituximab before conception. One of the infants was born with esophageal atresia, while the others were healthy. Pendergraft et al reported a miscarriage at 15 wk in a mother exposed to rituximab 7.5 mo prior to conception. Histologic and genetic evaluation of fetus revealed Beckwith-Wiedemann Syndrome. Ojeda-Uribe et al reported two successful outcomes in two women with autoimmune diseases received rituximab in the first trimester of pregnancy.
Preconception and first trimester exposure to rituximab seems not to indicate an excess risk of adverse fetal outcomes. Exposure during second and third trimesters causes decrease in B cells in the fetus. Further studies, especially prospective registries are needed to explore immune response to vaccines and perinatal infections in infants born to mothers received rituximab during second and third trimesters.
Abatacept (CTLA4-Ig) is a recombinant fusion protein that modulates T cell costimulatory signal mediated through the CD28-CD80/86 pathway. It has been approved for the treatment of refractory RA. Abatacept therapy should be stopped three months before conception. Ojeda-Uribe et al reported a healthy infant born to a 33-year-old mother exposed to abatacept in the first trimester.
Since TNF inhibitors are classified in FDA category B, they are safer than synthetic Disease Modifying Anti Rheumatic Drugs such as methotrexate and leflunomide. Although sporadic cases of congenital malformations have been reported in newborns born to mothers exposed to biologics, these rates appear to be comparable with those expected in the general population. Maternal exposure to TNF inhibitors at conception seems not to be related to adverse pregnancy outcomes. TNF inhibitors do not pass through the placenta during the first trimester, but they cross the placenta during the late second and third trimester. They can be used in the first trimester if no therapeutic alternative is available. But use of these agents in late second and third trimester should be reconsidered more carefully because of high placental transfer. Collected experience does not suggest an increased risk of opportunistic infections in pregnant patients and fetus. However, in case of exposure to these agents in the late second and third trimester, live vaccines should not be administered in the first six months of life because of increased risk for infections.
Abatacept and tocilizumab are classified as FDA pregnancy category C, and they should be discontinued three months before conception. Experiences with use of anakinra and rituximab during pregnancy are limited, larger studies are needed to bring further clarity.
The decision to use biologic agents during pregnancy is difficult. The benefits of biologic agents must outweigh the risks to the fetus/embryo or the mother. Larger and further studies are needed to demonstrate the safety of these agents during pregnancy.
|1.||Hazes JM, Coulie PG, Geenen V, Vermeire S, Carbonnel F, Louis E, Masson P, De Keyser F. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford). 2011;50:1955-1968. [PubMed] [DOI] [Cited in This Article: ]|
|2.||Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med. 1993;329:466-471. [PubMed] [DOI] [Cited in This Article: ]|
|3.||Reed SD, Vollan TA, Svec MA. Pregnancy outcomes in women with rheumatoid arthritis in Washington State. Matern Child Health J. 2006;10:361-366. [PubMed] [DOI] [Cited in This Article: ]|
|4.||Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Obstetrical and neonatal outcome in pregnant patients with rheumatic disease. Scand J Rheumatol Suppl. 1998;107:109-112. [PubMed] [Cited in This Article: ]|
|5.||Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES. Association of rheumatologic disease with preeclampsia. Obstet Gynecol. 2004;103:1190-1193. [PubMed] [DOI] [Cited in This Article: ]|
|6.||de Man YA, Hazes JM, van der Heide H, Willemsen SP, de Groot CJ, Steegers EA, Dolhain RJ. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 2009;60:3196-3206. [PubMed] [DOI] [Cited in This Article: ]|
|7.||Bowden AP, Barrett JH, Fallow W, Silman AJ. Women with inflammatory polyarthritis have babies of lower birth weight. J Rheumatol. 2001;28:355-359. [PubMed] [Cited in This Article: ]|
|8.||Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185-1206. [PubMed] [DOI] [Cited in This Article: ]|
|9.||Davies R, Dixon WG, Watson KD, Lunt M, Symmons DP, Hyrich KL. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Ann Rheum Dis. 2013;72:461-462. [PubMed] [DOI] [Cited in This Article: ]|
|10.||Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015;14:571-582. [PubMed] [DOI] [Cited in This Article: ]|
|11.||Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-790. [PubMed] [Cited in This Article: ]|
|12.||Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PubMed] [DOI] [Cited in This Article: ]|
|13.||Williams M, Chakravarty EF. Rheumatoid arthritis and pregnancy: impediments to optimal management of both biologic use before, during and after pregnancy. Curr Opin Rheumatol. 2014;26:341-346. [PubMed] [DOI] [Cited in This Article: ]|
|14.||Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis. Expert Rev Clin Immunol. 2009;5:27-34. [PubMed] [DOI] [Cited in This Article: ]|
|15.||Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf. 2012;11:1-5. [PubMed] [DOI] [Cited in This Article: ]|
|16.||Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, Kohout P, Shonova O, Lukas M. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48:951-958. [PubMed] [DOI] [Cited in This Article: ]|
|17.||Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-292; quiz e24. [PubMed] [DOI] [Cited in This Article: ]|
|18.||Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317:32-38. [PubMed] [DOI] [Cited in This Article: ]|
|19.||Burt MJ, Frizelle FA, Barbezat GO. Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody). J Gastroenterol Hepatol. 2003;18:465-466. [PubMed] [DOI] [Cited in This Article: ]|
|20.||Sinha A, Patient C. Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (Etanercept). J Obstet Gynaecol. 2006;26:689-691. [PubMed] [DOI] [Cited in This Article: ]|
|21.||Takayama K, Ishikawa S, Enoki T, Kojima T, Takeuchi M. Successful treatment with infliximab for Behçet disease during pregnancy. Ocul Immunol Inflamm. 2013;21:321-323. [PubMed] [DOI] [Cited in This Article: ]|
|22.||Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn’s disease of an ileoanal pouch during pregnancy. Dig Dis Sci. 2006;51:2045-2047. [PubMed] [DOI] [Cited in This Article: ]|
|23.||Akinci A, Ozçakar L. Infliximab use during pregnancy revisited. Acta Reumatol Port. 2008;33:374-375. [PubMed] [Cited in This Article: ]|
|24.||Kraemer B, Abele H, Hahn M, Rajab T, Kraemer E, Wallweiner D, Becker S. A successful pregnancy in a patient with Takayasu’s arteritis. Hypertens Pregnancy. 2008;27:247-252. [PubMed] [DOI] [Cited in This Article: ]|
|25.||Hou JK, Mahadevan U. A 24-year-old pregnant woman with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009;7:944-947. [PubMed] [DOI] [Cited in This Article: ]|
|26.||Umeda N, Ito S, Hayashi T, Goto D, Matsumoto I, Sumida T. A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Intern Med. 2010;49:187-189. [PubMed] [DOI] [Cited in This Article: ]|
|27.||Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology. 2010;220:71-76. [PubMed] [DOI] [Cited in This Article: ]|
|28.||Jang YW, Park YS, Kim SH, Jo YJ, Jo YK, Ahn SB, Seo YS, Hong YO. [A case of Crohn’s disease having normal delivery after infliximab treatment during early pregnancy]. Korean J Gastroenterol. 2013;61:37-41. [PubMed] [Cited in This Article: ]|
|29.||Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut. 2005;54:890. [PubMed] [DOI] [Cited in This Article: ]|
|30.||Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn’s disease. Aliment Pharmacol Ther. 2005;21:733-738. [PubMed] [DOI] [Cited in This Article: ]|
|31.||Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Lioté F, Goeb V, Azaïs I, Martin A, Pallot-Prades B, Maugars Y. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2009;76:28-34. [PubMed] [DOI] [Cited in This Article: ]|
|32.||Murashima A. [Treatment of patients with rheumatoid arthritis who desire to become pregnant--successful pregnancy in three cases treated with etanercept]. Nihon Rinsho. 2008;66:2215-2220. [PubMed] [Cited in This Article: ]|
|33.||Rump JA, Schönborn H. [Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment]. Z Rheumatol. 2010;69:903-909. [PubMed] [DOI] [Cited in This Article: ]|
|34.||Argüelles-Arias F, Castro-Laria L, Barreiro-de Acosta M, García-Sánchez MV, Guerrero-Jiménez P, Gómez-García MR, Cordero-Ruiz P, Iglesias-Flores E, Gómez-Camacho F, Domínguez-Muñoz EJ. Is safety infliximb during pregnancy in patients with inflammatory bowel disease? Rev Esp Enferm Dig. 2012;104:59-64. [PubMed] [Cited in This Article: ]|
|35.||Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84. [PubMed] [DOI] [Cited in This Article: ]|
|36.||Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol. 2003;30:241-246. [PubMed] [Cited in This Article: ]|
|37.||Hyrich KL, Symmons DP, Watson KD, Silman AJ. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 2006;54:2701-2702. [PubMed] [DOI] [Cited in This Article: ]|
|38.||Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36:635-641. [PubMed] [DOI] [Cited in This Article: ]|
|39.||Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823-826. [PubMed] [DOI] [Cited in This Article: ]|
|40.||Offiah M, Brodell RT, Campbell LR, Wyatt JP. Collodion-like membrane in a newborn exposed to infliximab. J Am Acad Dermatol. 2014;71:e22-e23. [PubMed] [DOI] [Cited in This Article: ]|
|41.||Guiddir T, Frémond ML, Triki TB, Candon S, Croisille L, Leblanc T, de Pontual L. Anti-TNF-α therapy may cause neonatal neutropenia. Pediatrics. 2014;134:e1189-e1193. [PubMed] [DOI] [Cited in This Article: ]|
|42.||Bogas M, Leandro MJ. Biologic therapy and pregnancy. A systematic literature review. Acta Reumatol Port. 2011;36:219-232. [PubMed] [Cited in This Article: ]|
|43.||Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn’s disease. Am J Gastroenterol. 2001;96:2274-2275. [PubMed] [DOI] [Cited in This Article: ]|
|44.||Grosen A, Julsgaard M, Christensen LA. Serum sickness-like reaction due to Infliximab reintroduction during pregnancy. J Crohns Colitis. 2013;7:e191. [PubMed] [DOI] [Cited in This Article: ]|
|45.||Ergaz Z, Bar-Oz B, Vainer GW, Abu-Leil S, Simanovsky N, Diav-Citrin O. Congenital fulminant Kaposiform hemangioendothelioma of the leg. Reprod Toxicol. 2014;50:1-3. [PubMed] [DOI] [Cited in This Article: ]|
|46.||Hultzsch S, Weber-Schoendorfer C, Schaefer C. Pregnancy outcomes after exposure to etanercept [abstract]. Reprod Toxicol. 2011;31:260. [DOI] [Cited in This Article: ]|
|47.||Weber-Schoendorfer C, Fritzsche J, Schaefer C. Pregnancy outcomes in women exposed to adalimumab or infliximab: The experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy [abstract]. Reprod Toxicol. 2011;31:267-268. [DOI] [Cited in This Article: ]|
|48.||Johnson DJ, Jones KL, Chambers CD, Salas E. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy Project [abstract]. Gastroenterol. 2009;136 suppl1:A27. [DOI] [Cited in This Article: ]|
|49.||Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-2392. [PubMed] [DOI] [Cited in This Article: ]|
|50.||Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4:603-605. [PubMed] [DOI] [Cited in This Article: ]|
|51.||Mahadevan U, Vermeire S, Wolf DC, Forger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Abbas S, Clowse MEB. Pregnancy outcomes after certalizumab pegol: results from safety surveillance [abstract]. J Crohn’s Colitis. 2014;8:S26. [DOI] [Cited in This Article: ]|
|52.||Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008. Natl Vital Stat Rep. 2012;60:1-21. [PubMed] [Cited in This Article: ]|
|53.||Mahadevan U, Martin CF, Dubinsky M, et al. Exposure to anti-TNF-alpha therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry [abstract]. Gastroenterology. 2014;146:S170. [DOI] [Cited in This Article: ]|
|54.||Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PubMed] [DOI] [Cited in This Article: ]|
|55.||Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol. 2007;58:138-149. [PubMed] [DOI] [Cited in This Article: ]|
|56.||Lau AG, Clark M, Harrison DD, Geldhof A, Nissinen R, Sanders M. Pregnancy outcomes in women exposed to golimumab [abstract]. Arthritis Rheum. 2013;65 Suppl 10:2041. [DOI] [Cited in This Article: ]|
|57.||Berger CT, Recher M, Steiner U, Hauser TM. A patient’s wish: anakinra in pregnancy. Ann Rheum Dis. 2009;68:1794-1795. [PubMed] [DOI] [Cited in This Article: ]|
|58.||Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Still’s disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol. 2011;29:1021-1023. [PubMed] [Cited in This Article: ]|
|59.||Chang Z, Spong CY, Jesus AA, Davis MA, Plass N, Stone DL, Chapelle D, Hoffmann P, Kastner DL, Barron K. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol. 2014;66:3227-3232. [PubMed] [DOI] [Cited in This Article: ]|
|60.||Rubbert-Roth A, Goupille PM, Moosavi S, Hou A. First experiences with pregnancies in RA patients (pts) receiving tocilizimab (TCZ) therapy [abstract]. Arthritis Rheum. 2010;62 Suppl 10:384. [DOI] [Cited in This Article: ]|
|61.||Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, Ternant D, Ardizzone M. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 2013;32:695-700. [PubMed] [DOI] [Cited in This Article: ]|
|62.||Ostensen M, Förger F. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011;23:293-298. [PubMed] [DOI] [Cited in This Article: ]|
|63.||Ton E, Tekstra J, Hellmann PM, Nuver-Zwart IH, Bijlsma JW. Safety of rituximab therapy during twins’ pregnancy. Rheumatology (Oxford). 2011;50:806-808. [PubMed] [DOI] [Cited in This Article: ]|
|64.||Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499-1506. [PubMed] [DOI] [Cited in This Article: ]|
|65.||Sangle SR, Lutalo PM, Davies RJ, Khamashta MA, D’Cruz DP. B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun. 2013;43:55-59. [PubMed] [DOI] [Cited in This Article: ]|
|66.||Pendergraft WF, McGrath MM, Murphy AP, Murphy P, Laliberte KA, Greene MF, Niles JL. Fetal outcomes after rituximab exposure in women with autoimmune vasculitis. Ann Rheum Dis. 2013;72:2051-2053. [PubMed] [DOI] [Cited in This Article: ]|